Two economies. One instrument.
What the United States supplies and what it receives. What the host country receives and what it retains. The same plant, read from both sides of the ledger, with the literature that makes each claim checkable.
The fragility is shared.
On 29 September 2024 a hurricane flooded one plant in North Carolina and hospitals across the United States began rationing intravenous fluid. The mechanism was the one every import-dependent ministry already knows: a single point of supply, outside the control of the people who need it.
of the nation’s IV fluids came from Baxter’s facilities when Hurricane Helene struck North Cove. Within weeks 86% of providers reported shortages and 54% held ten days or less of stock.[1] APSF · Nov 2024
products had shelf lives extended and sterile fluids were airlifted from overseas plants under FDA authorization; the shortage was declared over in August 2025 — eleven months later.[1][2] APSF · FDA
active drug shortages in the first quarter of 2024, the highest recorded, led by generic sterile injectables in crash carts and oncology.[3] ASHP · Apr 2024
of API manufacturers supplying the US market are overseas; 28% are domestic.[4] FDA testimony · Oct 2019
Hurricane Maria produced the same saline shortage from Puerto Rico. The pattern is structural; the pediatric pharmacy literature calls for a diversified supply chain at manufacturer and wholesaler level.[5] JPPT · Dec 2024
of Africa’s medicines are imported; over 95% of active ingredients; the continent produces about 3% of global medicines.[6] UNCTAD · Gavi VaccinesWork · 2025
of vaccines consumed in Africa are manufactured elsewhere. Africa CDC’s target: 60% of routine immunization needs made locally by 2040.[7][8] AUDA-NEPAD · Africa CDC
people lack access to safe, affordable surgical and anaesthesia care; 143 million additional procedures are needed every year. None happen without sterile fluids.[9] Lancet Commission on Global Surgery · 2015
children under five die of diarrhoea each year across 1.7 billion episodes; ORS costs cents, zinc shortens the episode by a quarter.[10] WHO · Mar 2024
adults will need insulin by 2030; about half will not have it on current trends. African need rises seven-fold.[11] Basu et al. · Lancet Diabetes & Endocrinology · 2018
A single point of supply is a single point of failure,
in any economy.
The United States discovered in 2024 what import-dependent health systems live with every year. The remedy is the same in both: sterile capacity, to one international standard, in more than one place, under governance that can be examined. That is the product.
What the United States supplies. What it receives.
Oggu Inc. is a United States institution. Its doctrine, intellectual property, governance and capital architecture are domiciled in Atlanta. Every plant it commissions abroad carries American standards, American engineering and American governance into a jurisdiction that would otherwise buy them from elsewhere — or not at all.
| Dimension | The United States supplies | The United States receives |
|---|---|---|
| Standards | Current Good Manufacturing Practice and the WHO Prequalification pathway the FDA’s regime aligns with; validation master plans, aseptic process simulation and batch-release discipline written to the US reference. | Allied sterile capacity built to a standard US regulators can recognize — the precondition for the temporary-importation mechanism the FDA used in 2024 and 2017 to be usable at all. [1][2] |
| Engineering and equipment | Blow-Fill-Seal line specification, water-for-injection, HVAC and cleanroom design, commissioning and qualification — specified and supervised from the United States. | An export market for US engineering, validation services, instrumentation and quality systems across every deployment, priced in dollars, paid by sovereign-aligned entities. |
| Governance and capital | Multi-entity governance, the R70 Covenant, the Beyond Operating System and the audit architecture — designed to the compliance frameworks of US DFC, IFC, EIB and FCDO. | Development-finance returns on infrastructure-grade assets; a headquarters, workforce and tax base in Atlanta; a governance model US institutions can examine on their own terms. The IFC–DFC–DEG–Proparco €500 million commitment to African insulin and vaccine manufacturing in 2024 shows the asset class is already financed. [12] |
| Strategic health security | Distributed sterile manufacturing on two continents that the United States neither owns nor controls today. | Reduced pressure on the same overseas API and finished-dose sources the US itself depends on [4]; a reserve of sterile essentials in allied jurisdictions when a domestic site fails; and disease-surveillance proximity through the Centers of Excellence. Pathogens do not recognize frontiers — Axiom III is a security statement. |
| Policy alignment | An operator that executes what US policy has already named: the 2021 supply-chain review that listed pharmaceuticals and APIs among four critical supply chains [13], and the DFC mandate to finance health infrastructure in partner countries [12]. | A private, US-domiciled instrument through which those policies produce plants rather than reports — under governance built to be examined. |
None of this is charity flowing outward. It is American standards, engineering and capital deployed as infrastructure, returning as resilience, exports and governance-grade assets. The doctrine is written in Atlanta because Atlanta is where it is examined.
What the host country receives. What it retains.
The Sovereign Compact states the terms. This page states the evidence a Minister of Health, Finance or Agriculture can cite when the compact reaches cabinet.
| Outcome | Mechanism | Evidence a minister can cite |
|---|---|---|
| Surgery, obstetrics, emergency care continue | Large-volume parenterals manufactured in-country on Blow-Fill-Seal lines to WHO Prequalification; supply continuity audited at the Center of Excellence. | Five billion people lack safe surgical care; 143 million additional procedures a year are needed. [9] A single flooded plant closed US operating rooms for months. [1][2] |
| Child mortality from diarrhoea falls | ORS and zinc as the adjacent line, sharing the plant’s quality system and distribution channel. | 443,832 under-five deaths a year; treatment costs cents; zinc shortens episodes by 25%. [10] |
| Insulin no longer depends on a border | Distributed local insulin manufacturing through full-stack Biotech; fill-finish under the same aseptic platform. | 79 million adults will need insulin by 2030; half will lack access; African need rises seven-fold. [11] |
| Foreign exchange stays in-country | Import substitution of the highest-volume essential-medicine category; plant-based inputs sourced under contracted offtake; surplus escrow-locked in-country under the R70 Covenant. | Over 70% of medicines and 95% of active ingredients are imported today; every unit produced at home is foreign exchange retained. [6] |
| A regulator with a prequalified site | Host-country registration pursued in parallel with WHO Prequalification; national inspectors work a site built to the international standard. | WHA74.6 (2021) commits member states to strengthening local production of medicines and health technologies; Africa CDC has set the 2040 vaccine target. [8][14] |
| Rural income and skilled employment | Agricultural offtake at the farm gate; a trained sterile-manufacturing workforce; Centers of Excellence as clinical employers. | The Cultivate stage routes pharmaceutical demand into farmer income in local currency; the platform reports it as a component of Return on Humanity. |
The ledger balances only when it is read from both sides.
A deployment that served the host country and not the United States would be aid. One that served the United States and not the host country would be extraction. The platform is engineered so that neither reading is available: the same plant, the same standard, the same audit, entered in two ledgers.
Every figure on this page, sourced.
The platform cites; it does not assert. Figures are those of the institutions named, as published; the platform reports its own outcomes only when audited.
- Meyer PA, McAllister RK. The Sterile Intravenous (IV) Fluid Shortage Crisis Update. Anesthesia Patient Safety Foundation, 15 November 2024. apsf.org
- U.S. Food and Drug Administration; shortage resolution reported 12 August 2025. axios.com
- American Society of Health-System Pharmacists. Record 323 active drug shortages, Q1 2024. aha.org
- Woodcock J. Safeguarding Pharmaceutical Supply Chains in a Global Economy. Testimony before the U.S. House Committee on Energy and Commerce, 30 October 2019. fda.gov
- Aguero D, Allen D. Weathering the Storm: Commentary on the Hurricane Helene IV Fluid Shortage. J Pediatr Pharmacol Ther. 2024;29(6):667–669. pmc.ncbi.nlm.nih.gov
- Africa imports over 70% of its medicines (UNCTAD; Think Global Health). Gavi VaccinesWork / The Conversation, 14 October 2025. gavi.org
- AUDA-NEPAD. Strengthening Africa’s Capacity in Manufacturing Vaccines and Medicines, 15 February 2023. nepad.org
- Africa CDC. Partnerships for African Vaccine Manufacturing — 60% of routine immunization needs manufactured locally by 2040. africacdc.org
- Meara JG, et al. Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. The Lancet Commission on Global Surgery. Lancet. 2015;386:569–624. thelancet.com
- World Health Organization. Diarrhoeal disease — fact sheet, 7 March 2024. who.int
- Basu S, et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25–33 (online 21 November 2018). eurekalert.org
- IFC, Proparco, DEG and DFC support Aspen to strengthen Africa’s pharmaceutical sector — €500 million, 3 September 2024. ifc.org
- Executive Order 14017, America’s Supply Chains, 24 February 2021, and the 100-day review of June 2021 covering pharmaceuticals and active pharmaceutical ingredients.
- World Health Assembly resolution WHA74.6, Strengthening local production of medicines and other health technologies to improve access, 2021.
Dr. Rajgopal R. Oggu, M.D.
Founder & Chairman, Oggu Inc.
Atlanta, Georgia · United States
To one of us, is to all of us.